SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    A. Ong, V. W.-S. Wong, G. L.-H. Wong, H.-Y. Chan, C.-H. Tse, H. L.-Y. Chan, Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir, Alimentary Pharmacology & Therapeutics, 2011, 34, 8
  2. 2
    Ester Lopez-Suñé, Montse Tuset, Montse Laguno, Asunción Moreno, José M. Miró, Características de los fármacos antivíricos activos frente al virus de la hepatitis y el virus de la influenza: actualización 2009, Enfermedades Infecciosas y Microbiología Clínica, 2010, 28, 4, 253.e1

    CrossRef

  3. 3
    Choong Keun Cha, Hyeok Choon Kwon, Jae Youn Cheong, Sung Won Cho, Sun Pyo Hong, Soo-Ok Kim, Wang Don Yoo, Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B, Journal of Medical Virology, 2009, 81, 3
  4. 4
    Kazuhiko Hayashi, Yoshiaki Katano, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Hidemi Goto, Successful cessation of lamivudine using interferon in a patient with chronic hepatitis B who received prophylactic lamivudine treatment during chemotherapy, Clinical Journal of Gastroenterology, 2009, 2, 3, 210

    CrossRef

  5. 5
    Manoj Kumar, Shiv K Sarin, Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection, Expert Review of Gastroenterology & Hepatology, 2008, 2, 4, 465

    CrossRef

  6. 6
    G. Carosi, M. Rizzetto, Treatment of chronic hepatitis B: Recommendations from an Italian workshop, Digestive and Liver Disease, 2008, 40, 8, 603

    CrossRef

  7. 7
    Anna S. F. Lok, Brian J. McMahon, Chronic hepatitis B, Hepatology, 2007, 45, 2
  8. 8
    Kwan Sik Lee, Dong Joon Kim, Management of Chronic Hepatitis B, The Korean Journal of Hepatology, 2007, 13, 4, 447

    CrossRef

  9. 9
    Yoon Jun Kim, Byeong Gwan Kim, Jun-Oh Jung, Jung-Hwan Yoon, Hyo-Suk Lee, High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study, Journal of Gastroenterology, 2006, 41, 3, 240

    CrossRef

  10. 10
    M. SHERMAN, Personal view: the management of chronic hepatitis B infection, Alimentary Pharmacology & Therapeutics, 2006, 23, 7
  11. 11
    Kang Mo Kim, Won-Beom Choi, Young-Suk Lim, Han-Chu Lee, Young-Hwa Chung, Young-Sang Lee, Dong-Jin Suh, Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus, Journal of Korean Medical Science, 2005, 20, 5, 821

    CrossRef

  12. 12
    Yun-Fan Liaw, Nancy Leung, Richard Guan, George K.K. Lau, Ismail Merican, Geoff McCaughan, Edward Gane, Jia-Horng Kao, Masao Omata, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update, Liver International, 2005, 25, 3
  13. 13
    Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Molecular virology and drug resistance in antiviral therapy of chronic hepatitis B, Current Hepatitis Reports, 2005, 4, 1, 27

    CrossRef

  14. 14
    Jeong Won Jang, Jong Young Choi, Si Hyun Bae, Seung Kew Yoon, Chang Wook Kim, Soon Woo Nam, Chang Don Lee, Young Sok Lee, Sang Bok Cha, Kyu Won Chung, Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients, Journal of Medical Virology, 2005, 77, 3
  15. 15
    Yun-Fan Liaw, The current management of HBV drug resistance, Journal of Clinical Virology, 2005, 34, S143

    CrossRef

  16. 16
    Emma C Thomson, Janice Main, Advances in hepatitis B and C, Current Opinion in Infectious Diseases, 2004, 17, 5, 449

    CrossRef

  17. 17
    Young-Suk Lim, Dong Jin Suh, Current Antiviral Therapy for Chronic Hepatitis B, Journal of Korean Medical Science, 2004, 19, 4, 489

    CrossRef

  18. 18
    Nancy Leung, Lamivudine for chronic hepatitis B, Expert Review of Anti-infective Therapy, 2004, 2, 2, 173

    CrossRef